Comparative bioavailability of lornoxicam as single doses of quick-release tablet, standard tablet and intramuscular injection: A randomized, open-label, crossover phase I study in healthy volunteers

Clinical Drug Investigation

Volumn 28, Issue 6, 2008, Pages 345-351

  Radhofer Welte, Susanna ^a,b   Dittrich, Peter ^c   Simin, Marija ^a,b   Branebjerg, Poul Erik ^a,b  

^a Nycomed Denmark   (Denmark)

^b Medical Scientific Strategy and Medical Marketing   (Austria)

^c UNIVERSITY OF GRAZ   (Austria)

Author keywords

Bioequivalence; Lornoxicam, pharmacokinetics; Nonsteroidal anti inflammatories, pharmacokinetics

Indexed keywords

LORNOXICAM;

ABSENCE OF SIDE EFFECTS; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM COMPARISON; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NORMAL HUMAN; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; PIROXICAM; TABLETS;

EID: 43649100267     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200828060-00002     Document Type: Article

References (13)

1. Bernstein RM, Frenzel W. A comparative study of two dosage regimens of lornoxicam and a standard dosage of naproxen in patients with rheumatoid arthritis. Eur J Clin Res 1995; 7: 259-73
2. Kidd B, Frenzel W. A multicenter, randomized, double blind study comparing lornoxicam with diclofenac in osteoarthritis. J Rheumatol 1996; 23 (9): 1605-11
3. Hitzenberger G, Radhofer-Welte S, Takacs F, et al. Pharmacokinetics of lornoxicam in man. Postgrad Med J 1990; 66 Suppl. 4: S22-6
4. Skjodt NM, Davies NM. Clinical pharmacokinetics of lornoxicam: a short half-life oxicam. Clin Pharmacokinet 1998 Jun; 34 (6): 421-8
5. Radhofer-Welte S, Dittrich P. Determination of the novel non-steroidal anti-inflammatory drug lornoxicam and its main metabolite in plasma and synovial fluid. J Chromatogr B Biomed Sci Appl 1998 Apr; 707 (1-2): 151-9
6. EMEA. The Committee for Proprietary Medicinal Products (CPMP). Note for guidance on the investigation of bioavailability and bioequivalence, CPMP/EWP/QWP/1401/98: 2001 Jun 21
7. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15 (6): 657-80
8. Kim YH, Ji HY, Park ES, et al. Liquid chromatography-electrospray ionization tandem mass spectrometric determination of lornoxicam in human plasma. Arch Pharm Res 2007 Jul; 30 (7): 905-10
9. Yakhno N, Guekht A, Skoromets A, et al. Analgesic efficacy and safety of lornoxicam quick-release formulation compared with diclofenac potassium: randomised, double-blind trial in acute low back pain. Clin Drug Invest 2006; 26 (5): 267-77
10. Bonnabry P, Leemann T, Dayer P. Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam. Eur J Clin Pharmacol 1996; 49 (4): 305-8
11. Si D, Guo Y, Zhang Y, et al. Identification of a novel variant CYP2C9 allele in Chinese. Pharmacogenetics 2004; 14 (7): 465-9
12. Guo Y, Zhang Y, Wang Y, et al. Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans. Drug Metab Dispos 2005; 33 (6): 749-53
13. Mayerhofer S, Welte S, Magometschnigg D, et al. The effect of food on pharmacokinetic parameters of the new NSAID lornoxicam in healthy volunteers [abstract]. 3rd Interscience World Conference on Inflammation, Antirheumatics, Analgesics and Immunmodulators; 1989 Mar 15-18, Monte Carlo, 223